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Background: Despite advances in endovascular techniques, infrapopliteal bypasses are still required for limb salvage.
Short-term graft patency is an important outcome parameter reﬂecting technical considerations and acute graft throm-
bosis. Both are important prerequisites for long-term patency. In this analysis, we compared the 30-day patency of all
conduit conﬁgurations for infrapopliteal bypasses.
Methods: All primary infrapopliteal bypasses from the American College of Surgeons-National Surgical Quality
Improvement Program database between 2005 and 2010 were divided into six groups: (1) great saphenous vein (GSV);
(2) prosthetic conduit (prosthetic); (3) prosthetic conduit with a distal anastomotic venous adjunct (ADJ), such as a cuff
or patch (prosthetic D ADJ); (4) composite graft of prosthetic and a vein segment (composite); (5) spliced autogenous
vein (spliced vein); and (6) arm vein. Thirty-day graft failure, patient demographics, and operative details were compared
among groups. A multivariate model was used for statistical analysis.
Results: A total of 5375 infrapopliteal bypasses were analyzed by conduit: GSV, 3983 (75%); prosthetic, 898 (17%);
spliced vein, 160 (3%); prosthetic D ADJ, 112 (2%); arm vein, 93 (2%); and composite, 91 (2%). The difference among
groups in demographics and comorbidities was not statistically signiﬁcant. Perioperative mortality rates were similar
among different conduits. After adjusting for sex, age, weight, race, and previous cardiac surgery, the bypass conduit had
a signiﬁcant independent association with 30-day graft patency (P [ .006). The GSV failure rate was 7.5%. Composite
had a signiﬁcantly higher 30-day failure rate (15.4%, P[ .006). There was no signiﬁcant difference in 30-day failure rate
of spliced vein (5.6%, P [ .37) or arm vein (4.3%, P [ .24) conduits compared with GSV. Prosthetic had signiﬁcantly
higher 30-day failure rate than GSV (10.5%, P[ .004). The addition of adjuvant venous tissue at the distal anastomosis
of prosthetic bypasses did not signiﬁcantly improve their 30-day patency (failure rate of 9.8% for prostheticD ADJ and
10.5% for prosthetic). There was no signiﬁcant difference in graft patency between alternative venous conduits (arm vein/
spliced vein) and prosthetic D ADJ.
Conclusions: Venous conduits (GSV, spliced vein, arm vein) deliver the best 30-day patency for infrapopliteal bypasses,
and GSV remains the most commonly used graft. Prosthetic grafts had a higher 30-day failure rate. Composite grafts
should be abandoned because their early patency is not better than pure prosthetic conduits. The addition of a distal
venous adjunct did not seem to improve acute prosthetic graft patency, which may reﬂect lack of effect on thromboge-
nicity rather than the myointimal hyperplastic response that effects long-term failure of infrapopliteal bypass. (J Vasc Surg
2014;59:1003-8.)Great saphenous vein (GSV) is the best conduit for
infrapopliteal bypasses because of its unparalleled long-
term patency of up to 70% at 5 years.1 Unfortunately,
30% of patients lack suitable saphenous veins at the initial
surgery, and w50% lack this conduit at the second bypass.
The most readily available alternative for GSV is off-the-
shelf prosthetic conduits such as polytetraﬂuoroethylene
(PTFE) or Dacron (DuPont, Wilmington, Del) grafts.
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very dismal, only 12% at 2 years.2 As a result, many
surgeons advocate use of alternative autogenous venous
conduits, such as arm vein, in a single segment, or spliced
veins in multiple segments. Other alternatives are
a composite of prosthetic and vein or prosthetic with distal
venous adjuvants such as the Miller cuff, the Taylor patch,
or the distal vein patch.
The performance of these alternative conduits for
infrainguinal bypasses is heavily scrutinized in the literature.
Faries et al3 analyzed their extensive experience using
autogenous veins for lower extremity bypasses and re-
ported that the primary patency of spliced vein was mark-
edly superior to composite. The difference was detected
as early as 1 year but was most profound at 5 years. The
5-year primary patency was 54% for autogenous conduits
and 0%, for composite grafts; furthermore, no difference
was found in long-term patency between single-segment
arm vein and multiple-segment spliced veins (55% at
5 years).3
Nevertheless, because harvesting and splicing multiple
segments of arm vein is a time-consuming process with
questionable long-term performance, many surgeons1003
Table I. A, Current Procedural Terminology (CPT)
codes for femoral-tibial bypasses
CPT codes Procedure
35566 Bypass graft, with vein; femoral-tibial/peroneal or
other distal vessels
35500 Harvest of upper extremity vein, 1 segment, for lower
extremity or CABG
35682 Bypass graft; autogenous composite, 2 segments of
veins
35683 Bypass graft; autogenous composite, 3 or more
segments of vein
35666 Bypass graft, with other than vein; femoral tibial/
peroneal
35685 Placement of vein patch or cuff at distal anastomosis
of synthetic graft
35681 Bypass graft; composite, prosthetic and vein
CABG, Coronary artery bypass grafting.
Table I. B, Study groups based on Current Procedural
Terminology (CPT) codes
CPT codes Groups
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venous adjuvant to improve long-term patency instead of
using spliced veins. In fact, data from the Albany group
suggested equivalent 2-year primary patency (45%-50%)
between spliced veins and prosthetic graft with a distal
venous adjuvant.4 More recently, we reported even better
performance of infrainguinal bypasses using distal vein
patch, with a 4-year primary patency of 62%.5
Most existing data in the literature on the performance
of various conduits for lower extremity bypasses are derived
from a heterogeneous group of all infrainguinal bypasses,
including femoral-popliteal, femoral-tibial, and popliteal-
tibial bypasses. Because infrapopliteal bypasses with pros-
thetic grafts have very inferior patency and limb salvage
rates compared with autogenous vein bypasses, we per-
formed this study with the speciﬁc focus on the perfor-
mances of adjuvant venous techniques only for
infrapopliteal bypasses by comparing them to GSV bypass
as the gold standard. Subsequently, we asked whether
alternative venous conduits, such as arm veins and spliced
veins, are worth the trouble by comparing those with pros-
thetic with distal venous adjuvant.35566 GSV
35566 þ 35500 Arm vein
35566 þ 35682/or 35683 Spliced vein
35666 Prosthetic
35666 þ 35685 Prosthetic þ distal ADJ
35666 þ 35681 Composite
ADJ, Adjunct; GSV, great saphenous vein.METHODS
This was a retrospective cohort study that used a large
national database of prospectively collected data of surgical
bypasses in the American College of Surgeons National
Surgical Quality Improvement Program (ACS-NSQIP)
Participant Use Data Files. The study cohort consisted of
all primary infrapopliteal bypasses entered in the ACS-
NSQIP database from 2005 to 2010. The data were
queried and divided into six different groups by the
Current Procedural Terminology (CPT) codes (American
Medical Association, Chicago, Ill) listed in Table I, A
and B.
All inﬂow vessels were femoral arteries and the target
vessels were “tibial/peroneal or other distal vessels.” All
autologous venous conduits had the base CPT code of
35566. GSV conduits in any conﬁguration (reversed, non-
reversed, or in situ) had the code 35566. The CPT code
35500 was added if the conduits were single-segment
arm veins. Spliced veins were composed of two or more
segments of autologous veins with the additional CPT
codes 35682 or 35683. Although conduits made from
spliced veins could potentially contain a piece of arm
vein, the difference between these two entities was that
arm veins were single-segment conduits and spliced veins
were not. The CPT code 35666 served as the base code
for prosthetic grafts, which is deﬁned as “bypass graft
with other than vein.” Because no current CPT code desig-
nates cadaveric saphenous veins, knowing with certainty
which group these conduits belong to is difﬁcult. For
composite grafts, the CPT code 35681 was added to
35666. All prosthetic grafts with any conﬁguration of distal
venous adjuvant (Linton, Miller, Taylor patch/cuff) had
the additional CPT code 35685. Although a distal vein
cuff could be performed in some composite conﬁgurationin clinical practice, this study speciﬁcally excluded these
to avoid overlapping among the groups.
Outcomes. The study focused on 30-day outcomes,
primarily comparing graft failure rates of all the possible
conduits, using the application of the GSV as the reference.
Graft failure is deﬁned in the NSQIP database as
“mechanical failure of an extracardiac graft or prosthesis
including myocutaneous ﬂaps and skin grafts requiring
return to the operating room, interventional radiology, or
a balloon angioplasty #30 days of the operation.” Distal
arteriovenous ﬁstula as an adjunct to maintain graft patency
was excluded from the study because of its inherent bias
toward better patency. Other exclusion criteria included
the concomitant performance of a major amputation of the
ipsilateral limb and simultaneous performance of other
major operative procedures, such as inﬂow procedures,
aneurysm repairs, thrombectomy, embolectomy, or reo-
perative procedures.
Preoperative patient characteristics examined included
age, weight, sex, race, American Society of Anesthesiolo-
gists ASA Physical Status Classiﬁcation, cardiac risks
(smoking, diabetes, congestive heart failure, myocardial
infarction, previous percutaneous coronary intervention,
or coronary artery bypasses), chronic obstructive pulmo-
nary disease, acute kidney injury, dialysis, the presence of
rest pain, and surgical emergency status. Operative details
recorded included procedure duration and the amount of














Femalea 1280 (32.2) 49 (31.2) 23 (24.7) 315 (35.2) 33 (29.7) 39 (42.9)
Age, yearsa 69.5 6 12.3 71.3 6 11.2 67.5 6 10.9 70.6 6 11.4 70.2 6 12.0 70.9 6 11.3
Weight, lbb 175.1 6 43.1 173.1 6 38.5 189.2 6 45.9 172.0 6 42.0 166.2 6 34.5 176.0 6 55.0
African Americanb 461 (11.6) 14 (8.8) 5 (5.4) 113 (12.6) 20 (17.9) 20 (22.0)
Smoker 1450 (36.4) 53 (33.1) 26 (28.0) 283 (31.5) 42 (37.5) 34 (37.4)
COPD 471 (11.8) 18 (11.3) 10 (10.8) 97 (10.8) 19 (17.0) 10 (11.0)
DM 1868 (46.9) 74 (46.3) 42 (45.2) 416 (46.3) 55 (49.1) 43 (47.3)
CHF 137 (3.4) 9 (5.6) 1 (1.1) 29 (3.2) 4 (3.6) 4 (4.4)
MI 100 (2.5) 6 (3.8) 3 (3.2) 25 (2.8) 4 (3.6) 0 (0)
PCI 772 (19.4) 34 (21.3) 13 (14.0) 153 (17.0) 23 (20.5) 14 (15.4)
Angina 85 (2.1) 4 (2.5) 4 (4.3) 25 (2.8) 1 (0.9) 1 (1.1)
CABGb 874 (21.9) 55 (34.4) 43 (46.2) 311 (34.6) 41 (36.6) 22 (24.2)
Renal failure 64 (1.6) 2 (1.3) 0 (0) 11 (1.2) 5 (4.5) 3 (3.3)
Dialysis 358 (9.0) 12 (7.5) 1 (1.1) 77 (8.6) 10 (8.9) 6 (6.6)
Rest pain 2356 (59.2) 104 (65.0) 61 (65.6) 534 (59.5) 74 (66.1) 53 (58.2)
Emergencya 209 (5.3) 8 (5.0) 6 (6.5) 73 (8.1) 6 (5.4) 9 (9.9)
ADJ, Adjunct; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; DM, diabetes mellitus;
GSV, great saphenous vein; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
aP < .05.
bP <.01 by one-way analysis of variance test across all groups.
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included mortality; cardiac, pulmonary (prolonged intuba-
tion, pulmonary embolism, reintubation, or pneumonia),
and renal (acute kidney injury or dialysis occurred in
patients without previous dialysis) complications; wound
infection; and graft failure.
Statistical analysis. Associations between patient
factors and outcomes of various conduits were tested using
c2 or the Fisher exact test for categoric variables and anal-
ysis of variance for continuous variables. Variables that met
a P of <.20 in univariate analysis were used in a multivariate
model, using stepwise logistic regression to predict
patency. For continuous outcomes (surgery time, transfu-
sion units), multiple linear regression analysis was used
(with the SAS GLM procedure). All data analysis used
SAS 9.2 software (SAS Institute, Cary, NC). P < .05 was
considered statistically signiﬁcant.
RESULTS
There were 5337 infrapopliteal bypasses that met our
inclusion and exclusion criteria, 3983 (75%) of which
were with GSV. The second most common conduit was
prosthetic (898 [17%]), 160 (3%) were with spliced veins,
and the remaining cases were equally divided among
prosthetic þ adjunct (ADJ), arm vein, and composite (2%
each). The groups did not differ signiﬁcantly in preopera-
tive morbidities such as diabetes, smoking/chronic
obstructive pulmonary disease, cardiac history, or renal
function. Signiﬁcantly different preoperative variables
were sex, age, weight, race, previous coronary artery bypass
grafting surgeries, and emergency surgery. Although the
preoperative and postoperative Rutherford categories
were not recorded in the database, no difference in rest
pain was noted across the groups (Table II). Arm veinwas least likely found in women and African Americans,
whereas composite had the highest female and African
American proportion. As expected, almost 50% of arm
vein (vs 20% of GSV) already had previous coronary artery
bypasses. Prosthetic and composite had the highest
percentage of emergent cases.
Independent predictors of graft patency were sex, race,
and emergency surgery. Women had a 39% higher failure
rate than men, African Americans had a 42% higher failure
rate than Caucasians, and patients who had emergency
surgery had a 63% higher failure rate than those who had
elective surgery. These variables were included in multivar-
iate analysis.
No signiﬁcant difference was found among the groups
in mortality, postoperative cardiovascular events, pulmo-
nary complications, renal dysfunction, or wound infections
(Table III). Operative time was shortest with prosthetic
and longest in spliced vein, averaging 3.7 and 6.1 hours,
respectively. The average time for prosthetic þ ADJ was
equivalent to GSV, which was 4.4 hours. Spliced vein
required the most blood transfusion compared with the
other groups. The graft failure rate at 30 days was 7.5%
with GSV. Composite had the highest failure rate of 15%,
whereas the failure rate for prosthetic grafts with and
without ADJ was w10% (Table III).
All venous conduits as a group (GSV þ arm vein þ
spliced vein) had better performance than all the prosthetic
combinations as a group (prosthetic þ prosthetic/ADJ þ
composite), with a graft failure rate of 7.4% vs 11%, respec-
tively (P ¼ .0001). When autologous venous conduits were
compared against each other, there was no signiﬁcant
difference in 30-day graft failure rate between spliced
vein (5.6%, P ¼ not signiﬁcant [NS]) or arm vein (4.3%,
P ¼ NS) compared with GSV. Among all the prosthetic














Transfusion, unitsa 0.5 6 1.1 1.2 6 1.7 0.4 6 0.8 0.5 6 1.2 0.7 6 1.1 0.6 6 1.2
Operative time, hoursa 4.4 6 1.8 6.1 6 1.9 5.1 6 2.3 3.7 6 1.6 4.4 6 1.8 4.7 6 2.0
Mortality 127 (3.2) 4 (2.5) 2 (2.2) 40 (4.5) 1 (0.9) 4 (4.4)
Stroke 23 (0.6) 2 (1.3) 0 (0) 11 (1.2) 0 (0) 0 (0)
Myocardial infarction 81 (2.0) 5 (3.1) 2 (2.2) 24 (2.7) 2 (1.8) 1 (1.1)
Cardiac arrest 47 (1.2) 0 (0) 0 (0) 17 (1.9) 1 (0.9) 3 (3.3)
Renal dysfunction 51 (1.3) 1 (0.6) 1 (1.1) 15 (1.7) 1 (0.9) 2 (2.2)
Pulmonary complications 155 (3.9) 5 (3.1) 4 (4.3) 49 (5.5) 7 (6.3) 6 (6.6)
DVT 40 (1.0) 2 (1.3) 0 (0) 7 (0.8) 0 (0) 1 (1.1)
Wound infection 117 (2.9) 8 (5.0) 1 (1.1) 32 (3.6) 3 (2.7) 1 (1.1)
Length of stay, days 10.7 6 10.9 10.7 6 8.2 8.5 6 5.9 10.7 6 10.1 10.6 6 8.6 11.1 6 8.4
30-day graft failurea 300 (7.5) 9 (5.6) 4 (4.3) 94 (10.5) 11 (9.8) 14 (15.4)
ADJ, Adjunct; DVT, deep vein thrombosis; GSV, great saphenous vein.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).














Fig. Paired comparisons of all alternative conduits against great
saphenous vein (GSV) showed prosthetics without adjunct (ADJ)
and composite grafts had signiﬁcantly higher failure rates. Graft
failure rates of arm veins, spliced veins, and prosthetic with
a venous anastomotic ADJ were not signiﬁcantly different than
that of GSV.
JOURNAL OF VASCULAR SURGERY
1006 Nguyen et al April 2014conduits, although prosthetic þ ADJ had the lowest graft
failure rate, no statistical signiﬁcance was found between
this group and prosthetic alone (9.8% vs 10.5%, respec-
tively; P ¼ NS).
Paired comparison of graft failure rate between each of
the alternative conduits against the gold standard GSV
showed that the only two groups that were signiﬁcantly
worse than GSV were prosthetic and composite (P < .05;
Fig). After correcting for all the independent predictors
of graft failure, multivariate analysis showed some conduit
conﬁgurations were associated with graft failure; speciﬁ-
cally, prosthetic conduits had a 1.5-times higher failure
rate than GSV (P ¼ .004) and composite had twice the
failure rate of GSV (P ¼ .006).
Alternative venous conduits (spliced vein and arm vein)
were signiﬁcantly better than prosthetic or composite (graft
failure rate 5.1% vs 10.6% and 15.4%, respectively; P <
.05). Nevertheless, although graft failure rates of spliced
vein or arm vein was less than that of prosthetic þ ADJ,
the difference was not statistically signiﬁcant.
DISCUSSION
That GSV is the best conduit for femoral-infrapopliteal
bypasses for limb salvage is well established. In this study,
we scrutinized the performance of all alternative conduits
against the gold standard GSV using nationwide data.
Composite had the worst 30-day patency rate, followed
by prosthetic without ADJ. There appeared to be no signif-
icant difference in short-term graft patency among GSV,
arm vein, spliced vein, and prosthetic þ ADJ.
Even though this study did not detect signiﬁcant differ-
ences between GSV and arm vein/spliced vein at 30 days,
published long-term data have reported superior 2-year
primary patency of 61% for GSV of compared with 42%
for arm vein.6 Yet, in the absence of GSV, single-segment
arm vein appears to be the next best alternative to GSV,
with a 3-year primary patency as high as 50%.7 On one
hand, the venous conduits that serve as the alternatives
for GSV, such as arm veins and spliced veins, are not alwaysavailable, and their use requires a prolonged operative time
and increases the complexity of the operation. On the
other hand, off-the-shelf prosthetic conduits are a more
easily obtained alternative but have a dismal long-term
12% primary patency at 2 years2 and inferior short-term
patency compared with other conduits, as shown in this
study.
As a result, modiﬁcation with venous adjuvants at the
distal anastomosis has been used to improve patency. The
addition of distal vein adjuvants, such as cuffs and patches,
to prosthetic grafts has had the most signiﬁcant effect when
the distal anastomosis is beyond the popliteal artery,
JOURNAL OF VASCULAR SURGERY
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protective effects of distal venous adjuvant is believed to
be caused by the attenuation of myointimal hyperplasia,
which takes months to occur, it is not surprising that
this beneﬁt was not realized at 30 days, as shown in this
study.
Our data also suggest that the composite grafts have
a higher failure rate than prosthetic grafts. The exact reason
behind this ﬁnding remains unclear, but one can speculate
that the size mismatch of the prosthetic/veins anastomosis
is thrombogenic. Regardless of the exact etiology, the 30-
day graft patency of composite grafts was clearly inferior to
that of prosthetic grafts. Because early graft failure is known
to negatively affect long-term patency, the conﬁguration of
the composite conduit is not worth the additional effort
and time to pursue.
Although autogenous venous conduits as a group
clearly outperformed any prosthetic combinations (ie,
arm veins or spliced veins had better patency than pros-
thetic for infrapopliteal bypasses),8,9 which conduit is
better when alternative veins are compared with
prosthetic þ ADJ remains unclear. Our study showed no
signiﬁcant difference between these two conduit options
at 30 days. Similarly, a randomized study by Kreienberg
et al4 found comparable primary patency between spliced
veins and PTFE with venous cuff at 2 years of 45% to
50%.4 Thus, the choice of which conduit to use remains
with the operative surgeons because even though alterna-
tive veins are slightly more time-consuming, our study
showed major outcomes, such as mortality, cardiac, pulmo-
nary, renal, and wound infection rates, were not affected.
The limitations of this study include its retrospective
nature, although the data were collected prospectively.
Many relevant preoperative, intraoperative, and postopera-
tive details were missing in this national database. Neither
the status of the outﬂow targets, such as the number of
runoff vessels and wall calciﬁcation, nor the quality of the
venous conduits was known. The exact type of prosthetic
conduits used (PTFE, PROPATEN [W.L. Gore & Associ-
ates, Flagstaff, Ariz], or Dacron) and the length of the
conduits were some other relevant variables that were not
recorded. Because there are data that suggested better
1-year patency for PROPATEN than standard PTFE,10
the ability to differentiate these two prosthetic conduits
could have provided more accurate patency data. One
could argue that arm vein had the advantage of being the
shortest group of conduits because it was deﬁned as
single-segment in this study and hence had the best
patency because of this bias; however, this bias was not
statistically signiﬁcant and unlikely inﬂuenced the results
after the multivariate analysis.
The anticoagulation regimen across the different
groups and data on long-term follow-up >30 days were
not available in the NSQIP database. Nevertheless, the
large volume of cases collected from multiple institutions
across the nation allowed us to investigate all of the
different groups with adequate power to detect signiﬁcantdifferences and reﬂected real-world experience rather than
just the practice of a select few surgeons in one center.
Furthermore, although many single-institution studies
reported high long-term patency of arm veins and spliced
veins, those statistics came from a heterogeneous group
of all infrainguinal bypasses performed by highly experi-
enced surgeons who have been long-time advocates for
autogenous veins, which made it difﬁcult to generalize
the performance of these conduits across different settings.
Our study focused speciﬁcally on only femoral-
infrapopliteal bypasses and the nationwide database from
the NSQIP allows better generalization.
CONCLUSIONS
GSV remains the gold standard conduit for infrapopli-
teal bypasses. Alternative venous conduits, such as arm
veins or spliced veins, are comparable to saphenous veins
in 30-day patency. Composite grafts should be avoided
due to their high early graft failure rate. If prosthetic
conduits must be used, they should be performed with
a distal venous adjuvant. Because there were no detectable
differences between spliced vein or arm vein compared with
prosthetic þ ADJ at 30 days, the choice among these
conduits is still at the discretion of the surgeons until
more long-term comparative data are available.
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members, and guests, thank you for the privilege and being asked
to begin the discussion on this paper. The authors have queried the
NSQIP database over a recent 5-year interval and analyzed over
5300 tibial bypasses, assessing 30-day patency rates by conduit.
Nearly 75% of these used GSV and the remainder, various alterna-
tive conduits. This study does not attempt to address long-term
patency for which some of such venous adjuncts like the Taylor
patch or Miller cuff were theoretically developed to improve.
And though the authors conﬁrm the ﬁndings of others as to overall
inferior patency in African Americans and women, it does not give
any added insight as to why this is so.
However, the authors have succeeded in giving us a useful
snapshot of these early graft results that addresses a very real clin-
ical issue. Not surprisingly, the 30-day prosthetic patency and
composite graft patency were signiﬁcantly inferior to autogenous
great saphenous vein. Surprisingly, however, this difference at 30
days was only about 3% for prosthetic alone, and there was no
signiﬁcant difference for prosthetic with vein patch. Thus, they
conclude that while composite grafts are clearly inferior, a vein
patch at the distal prosthetic anastomosis may add to early graft
patency–even rivaling that for saphenous vein.
Like many large database analyses, the devil is in the details.
My ﬁrst question for the authors is could you clarify the prosthetic
graft type (heparin-bonded or -hooded) and antiplatelet and anti-
coagulation regimens that might contribute to such good early
prosthetic results?
Also of interest is that the composite spliced vein and arm vein
patencies were comparable to GSV at 30 days. My personal expe-
rience is that more than one splice becomes counterproductive.
Could the authors tell us how many splices are worthwhileeonly
one? Or, two or three–before beginning to approximate the
patency of a prosthetic?
Given the 30-40% increase in operative time with spliced or
arm vein compared to a prosthetic and vein patch, with no early
patency advantage, can the authors answer their own question:
when is it ever worthwhile to go to this extra effort?I enjoyed the presentation and once again thank the Associa-
tion for the privilege of opening the discussion.
Dr Bao-Ngoc Nguyen. Thank you, Dr Robison. I am going
to try to answer your questions in order. The ﬁrst question
regarding the kind of prosthetic conduits and the antiplatelet/anti-
coagulation regimens, unfortunately, one of the limitations of
using the NSQIP database, as you pointed out, is that it records
only 30-day outcomes. We queried the cases based on CPT codes,
and our current CPT codes only identify prosthetic conduits as
a whole without differentiating the different types of prosthetic
graft available. The use of antiplatelet or anticoagulation medica-
tions was also not recorded in the NSQIP database.
The second question regarding splicing multiple segments of
autologous veins and your observation that splicing more than
two pieces is no longer beneﬁcial, I could go back to the database
and subdivide spliced veins into two different groups of two versus
three or more segments because the CPT codes allow us to do
that. However, the number of each group would be lower and
the power of analysis might be lost.
The third question regarding how time-consuming splicing
vein is and whether using prosthetic with distal adjuvant could
be much quicker with potential equivalent results, this is a very
good question and it was the original question we raised in this
paper. In certain ways, 30-day graft patency is a prerequisite for
long-term patency. If the bypass is not patent at 30 days, the
chance that it is patent long-term is minimal. Therefore, the one
deﬁnitive answer suggested by the data of this paper is that
composite and prosthetic alone should not be used because the
30-day patency was signiﬁcantly worse than other conduits.
Unfortunately, we cannot answer deﬁnitively about splicing
veins versus prosthetic with distal adjuvant because they seem to
be equivalent at 30 days, yet the long-term data are lacking. We
think that the beneﬁt of distal venous adjuvant derives from atten-
uating myointimal hyperplasia, which is the main cause of graft
failure beyond 6 months. Since we don’t have this data beyond
30 days, the question of whether to use splicing veins or prosthetic
conduits with distal adjuvant remains unanswered.
